Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma

医学 内科学 肿瘤科 危险系数 放化疗 前瞻性队列研究 放射治疗 人口 化疗 食管癌 生物标志物 癌症 置信区间 环境卫生 生物化学 化学
作者
Hoi Yan Ng,Josephine Mun Yee Ko,Ka On Lam,Dora L.�W. Kwong,Anthony W.I. Lo,Yhi Wong,Claudia Lai Yin Wong,Siu Yin Chan,Kwan Kit Chan,Tsz Ting Law,Wei Dai,Henry Chun Hung Fong,Faith Sin Fai Choy,Chun Kit Lo,Cancan Chen,Simon Ying-Kit Law,Maria Li Lung
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:158 (11): 1141-1141 被引量:51
标识
DOI:10.1001/jamasurg.2023.4395
摘要

Importance: Esophageal squamous cell carcinoma (ESCC) is a deadly disease with frequent recurrence. There are unmet needs for prognostic biomarkers for dynamically monitoring disease progression and detecting minimal residual disease. Objective: To examine whether circulating tumor DNA is clinically useful as a prognostic biomarker for ESCC recurrence and patient survival. Design, Setting, and Participants: This single-center, population-based cohort study consecutively enrolled 147 patients receiving curative (n = 74) or palliative (n = 73) treatment at the surgery and clinical oncology departments of Queen Mary Hospital in Hong Kong from August 1, 2016, to September 31, 2021. Patients were followed up for 2 years. Plasma samples were collected at different longitudinal time points for a prospective circulating tumor DNA (ctDNA) next-generation sequencing profiling study of 77 actionable genes. Intervention: Patients were treated with up-front surgery, neoadjuvant chemoradiotherapy plus surgery with or without adjuvant therapy, or palliative chemotherapy (CT). Main Outcomes and Measures: Detection of circulating tumor DNA (ctDNA), progression-free survival (PFS), and overall survival (OS). Results: A total of 478 serial plasma samples from 147 patients with locoregional or metastatic ESCC were prospectively analyzed. Among the 74 patients in the curative group (median [range] age, 66 [46-85] years; 56 [76.0%] male), 44 (59.5%) relapsed and 36 (48.6%) died. For patients receiving curative surgical treatment, a high ctDNA level (hazard ratio [HR], 7.84; 95% CI, 1.87-32.97; P = .005) and ctDNA alterations (HR, 5.71; 95% CI, 1.81-17.97; P = .003) at 6 months postoperation were independently associated with poor OS. Among patients receiving neoadjuvant chemoradiotherapy, postneoadjuvant ctDNA alterations were associated with poor PFS (HR, 3.16; 95% CI, 1.17-8.52; P = .02). In the 73 patients in the palliative group (median [range] age, 63 [45-82] years; 63 [86.0%] male), 71 (97.3%) had disease relapse and 68 (93.2%) died. Detectable pre-CT NFE2L2 alterations were independently associated with PFS (HR, 2.99; 95% CI, 1.35-6.61; P = .007) and OS (HR, 28.39; 95% CI, 7.26-111.03; P = 1.52 × 10-6), whereas high ctDNA levels (HR, 2.41; 95% CI, 1.18-4.95; P = .02) and alterations in pre-cycle III ctDNA (HR, 1.99; 95% CI, 1.03-3.85; P = .04) showed weaker associations with PFS. Alterations in pre-CT ctDNA were independently associated with OS (HR, 4.46; 95% CI, 1.86-10.69; P = 7.97 × 10-4). Conclusions and Relevance: The findings of this cohort study indicate that prognostic models incorporating ctDNA features are useful in ESCC. Both ctDNA level and NFE2L2 alterations pre-CT and before cycle III were found to be important prognostic factors in palliative groups, and ctDNA alterations after treatment and at 6 months after surgery may define high-risk groups for recurrence in the curative group. High-risk patients can benefit by a timely switch to the next therapeutic options.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
桃酥完成签到,获得积分10
1秒前
1秒前
1秒前
Lucas的应助被乖猴猴采纳,获得10
1秒前
zee发布了新的文献求助10
1秒前
1秒前
赖羊羊发布了新的文献求助10
2秒前
冷酷的醉柳完成签到 ,获得积分10
2秒前
二懒完成签到 ,获得积分10
2秒前
2秒前
善良早晨发布了新的文献求助10
2秒前
ZJR发布了新的文献求助20
2秒前
3秒前
asdfghjkl完成签到,获得积分10
3秒前
我是谁的应助被赤侠采纳,获得50
4秒前
英姑的应助被小美采纳,获得10
4秒前
4秒前
4秒前
liury发布了新的文献求助10
4秒前
4秒前
归海听云发布了新的文献求助10
5秒前
叶子完成签到,获得积分10
5秒前
Solkatt发布了新的文献求助10
5秒前
li发布了新的文献求助10
6秒前
6秒前
Akim的应助被en采纳,获得10
7秒前
赖羊羊完成签到,获得积分10
7秒前
7秒前
leehong发布了新的文献求助10
7秒前
7秒前
7秒前
懒得起名完成签到,获得积分10
8秒前
8秒前
Muli完成签到 ,获得积分10
8秒前
8秒前
暖暖发布了新的文献求助10
8秒前
Maestro_S的应助被赤侠采纳,获得50
8秒前
9秒前
刘星星发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176748
求助须知:如何正确求助?哪些是违规求助? 9567993
关于积分的说明 21796041
捐赠科研通 7771502
什么是DOI,文献DOI怎么找? 3432161
关于科研通互助平台的介绍 2556472
邀请新用户注册赠送积分活动 2477761